Hirtle Callaghan & Co’s AstraZeneca AZN Stock Holding History

Hirtle Callaghan & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-551	Closed	-$39K	–	44
2014 Q4	$39K	Hold	551	–	–	0.01%	322
2014 Q3	$39K	Hold	551	–	–	0.01%	331
2014 Q2	$41K	Hold	551	–	–	0.01%	378
2014 Q1	$36K	Hold	551	–	–	0.01%	389
2013 Q4	$33K	Hold	551	–	–	﹤0.01%	377
2013 Q3	$29K	Buy	+551	New	+$27.7K	﹤0.01%	399

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Hirtle Callaghan & Co's AZN Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of AstraZeneca (AZN) in Q1 2015, closing a stake of 551 shares — an estimated $39K sold.

Hirtle Callaghan & Co first reported a position in AZN in Q3 2013 and held it in 6 quarters. The position peaked at $41K in Q2 2014. 386 funds tracked by Wall St. Rank hold AZN as of Q1 2015.

Hirtle Callaghan & Co reported no remaining AstraZeneca position as of Q1 2015 after selling out during the quarter.
Hirtle Callaghan & Co sold 551 AstraZeneca shares in Q1 2015, an estimated $39K.
Hirtle Callaghan & Co first reported a position in AstraZeneca in Q3 2013 and held it in 6 quarters.
Hirtle Callaghan & Co's AstraZeneca position peaked at $41K in Q2 2014.
386 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.